# The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

> **NCT00511823** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Nausea and Vomiting, Chemotherapy-Induced

## Interventions

- **DRUG:** casopitant
- **DRUG:** dolasetron
- **DRUG:** granisetron
- **DRUG:** rosiglitazone

## Key facts

- **NCT ID:** NCT00511823
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-23
- **Primary completion:** 2007-09-21
- **Final completion:** 2007-09-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2017-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00511823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00511823, "The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00511823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*